摘要
目的:分析与探讨采用腺苷蛋氨酸与还原型谷胱甘肽联合治疗急性药物性肝损伤患者的临床效果。方法:将2015年5月-2017年5月经本院治疗的76例急性药物性肝损伤患者选择为研究对象,按照随机数字表法分为对照组和观察组,每组38例。对照组给予腺苷蛋氨酸治疗,观察组在腺苷蛋氨酸基础上联合应用还原型谷胱甘肽治疗。比较两组的治疗效果、碱性磷酸酶(ALP)、丙氨酸转氨酶(ALT)、谷氨酰转肽酶(GGT)、总胆红素(TBil)等改善情况以及不良反应发生情况。结果:观察组的治疗总有效率97.37%、ALP(86.27±12.13)U/L、ALT(52.71±13.96)U/L、GGT(108.63±19.19)U/L、TBil(53.47±11.06)μmol/L,均明显优于对照组78.95%、(101.38±12.98)U/L、(110.14±13.02)U/L、(148.49±19.23)U/L、(76.25±11.25)μmol/L,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:采用腺苷蛋氨酸联合还原型谷胱甘肽治疗急性药物性肝损伤,能够有效控制病情发展,显著改善患者肝功能情况,且不良反应较少,临床治疗效果确切,有助于患者预后。
Objective:To analyze and explore clinical effect of Ademetionine and reduced Glutathione in the treatment of acute drug-induced liver injury(ADILI).Method:A total of 76 ADILI patients who treated in our hospital from May 2015 to May 2017 were selected as the research subjects,and they were divided into the control group and the observation group according to table of random number,38 cases in each group.The patients in the control group were given Ademetionine treatment,and the patients in the observation group were given reduced Glutathione on the basis of Ademetionine.The treatment effect,ALP,ALT,GGT,TBil improvements and adverse reactions were compared between the two groups.Result:The total effective rate(97.37%),ALP(86.27±12.13)U/L,ALT(52.71±13.96)U/L,GGT(108.63±19.19)U/L,and TBil(53.47±11.06)μmol/L in the observation group were significantly better than 78.95%,(101.38±12.98)U/L,(110.14±13.02)U/L,(148.49±19.23)U/L and(76.25±13.25)μmol/L in the control group,the differences were statistically significant(P<0.05).There was no significant difference in adverse reaction rate between the two groups(P>0.05).Conclusion:Ademetionine combined with reduced Glutathione in the treatment of acute drug-induced liver injury can effectively control the development of the disease,significantly improve the liver function of patients,and has fewer adverse reactions,which is effective in clinical treatment,and is helpful for the prognosis of patients.
作者
王宗源
WANG Zongyuan(Jingmen City Duodao People’s Hospital,Jingmen 448124,China)
出处
《中国医学创新》
CAS
2018年第6期57-60,共4页
Medical Innovation of China